Furoxan

Furoxan

SCHEMBL320190

N#Cc1c(-c2ccccc2)no[n+]1[O-]

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCC1 P33527 8/20 1.00
ALDH1A1 P00352 2/20 1.00
MAPT P10636 2/20 1.00
GMNN O75496 1/20 1.00
LMNA P02545 1/20 1.00
TP53 P04637 1/20 1.00
CYP1A2 P05177 1/20 1.00
CYP3A4 P08684 1/20 1.00
CYP2D6 P10635 1/20 1.00
TSHR P16473 1/20 1.00
NFKB1 P19838 1/20 1.00
THPO P40225 1/20 1.00
BLM P54132 1/20 1.00
PMP22 Q01453 1/20 1.00
SMN1; SMN2 Q16637 1/20 1.00
NPSR1 Q6W5P4 1/20 1.00
GSR P00390 3/20 0.68
ABCB1 P08183 5/20 0.54
CA12 O43570 4/20 0.50
CA1 P00915 4/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1547530 0.97 ABCC1 (0.94) ABCC1ALDH1A1MAPTGMNNLMNA
SCHEMBL1547974 0.91 ABCC1 (0.83) ABCC1ALDH1A1MAPTGMNNLMNA
SCHEMBL1547730 0.88 GSR (0.81) ABCC1ALDH1A1MAPTGMNNLMNA
SCHEMBL1547962 0.83 ABCC1 (0.71) ABCC1ALDH1A1MAPTGMNNLMNA
SCHEMBL1547742 0.83 ABCC1 (0.71) ABCC1ALDH1A1MAPTGMNNLMNA
SCHEMBL1547817 0.83 ABCC1 (0.71) ABCC1ALDH1A1MAPTGMNNLMNA
SCHEMBL1547686 0.83 ABCC1 (0.71) ABCC1ALDH1A1MAPTGMNNLMNA
SCHEMBL1548118 0.83 ABCC1 (0.71) ABCC1ALDH1A1MAPTGMNNLMNA
SCHEMBL1547733 0.82 GSR (1.00) ABCC1ALDH1A1MAPTGMNNLMNA
SCHEMBL1548123 0.82 GSR (0.71) ABCC1ALDH1A1MAPTGMNNLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025230907-A1 A CXCR4 ANTAGONIST, A STATS ACTIVATOR, AND/OR AN AGENT THAT INCREASES NITRIC OXIDE CONTENT FOR USE IN METHODS OF IMPROVING NERVE REGENERATION THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2025-11-06 WO claimed
EP-4470565-A1 METHOD FOR PREVENTING OR TREATING DISEASE OR DISORDER ASSOCIATED WITH ANTINEOPLASTIC AGENT OnQuality Pharmaceuticals China Ltd. (CN) 2024-12-04 EP claimed
CN-118742325-A Methods for preventing or treating diseases or conditions associated with antineoplastic agents 上海岸阔医药科技有限公司 2024-10-01 CN claimed
EP-4426274-A1 NITRIC OXIDE DONORS FOR USE IN SURGICAL RECOVERY Baxter International Inc. (US) 2024-09-11 EP claimed
US-20240285831-A1 METHODS OF USE OF MODULATORS TO IMPROVE NERVE REGENERATION KEEFER, Edward (US) 2024-08-29 US claimed
US-11969522-B2 Use of immune modulators to improve nerve regeneration THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2024-04-30 US claimed
WO-2023142996-A1 METHOD FOR PREVENTING OR TREATING DISEASE OR DISORDER ASSOCIATED WITH ANTINEOPLASTIC AGENT 上海岸阔医药科技有限公司 2023-08-03 WO claimed
WO-2023081681-A1 NITRIC OXIDE DONORS FOR USE IN SURGICAL RECOVERY BAXTER INTERNATIONAL INC. (US) 2023-05-11 WO claimed
US-20230140515-A1 NITRIC OXIDE DONORS FOR USE IN SURGICAL RECOVERY BAXTER INTERNATIONAL INC. 2023-05-04 US claimed
US-20180036314-A1 METHODS AND COMPOSITIONS FOR TREATING PERIPHERAL VASCULAR DISEASE EXODOS LIFE SCIENCES LP (US) 2018-02-08 US claimed
WO-2016065423-A1 METHOD AND COMPOSITIONS FOR PREVENTING BACTERIAL CORROSION OF A SUBSTRATE IXOM OPERATIONS PTY LTD (AU) 2016-05-06 WO claimed
CN-103429235-A Compounds for treating cancer and uses thereof LAI HUNG-CHENG 2013-12-04 CN claimed
US-20130261142-A1 COMPOUNDS USED FOR TREATING CANCER AND THE USE THEREOF NATIONAL DEFENSE MEDICAL CENTER (TW) 2013-10-03 US claimed
US-20130053393-A1 METHODS AND COMPOSITIONS FOR TREATING PERIPHERAL VASCULAR DISEASE EXODOS LIFE SCIENCES LIMITED PARTNERSHIP (US) 2013-02-28 US claimed
EP-2512479-A1 METHODS AND COMPOSITIONS FOR TREATING PERIPHERAL VASCULAR DISEASE Exodos Life Sciences Limited Partnership (US) 2012-10-24 EP claimed
WO-2012079232-A1 COMPOUNDS USED FOR TREATING CANCER AND THE USE THEREOF LAI HUNG-CHENG (CN) 2012-06-21 WO claimed
WO-2011075655-A1 METHODS AND COMPOSITIONS FOR TREATING PERIPHERAL VASCULAR DISEASE EXODOS LIFE SCIENCES LIMITED PARTNERSHIP (US) 2011-06-23 WO claimed
US-7910574-B2 Treatments for the control of schistosomiasis ILLINOIS STATE UNIVERSITY (US) 2011-03-22 US claimed
WO-2026107071-A1 COMBINATION THERAPY Retension Pharmaceuticals, Inc. (US) 2026-05-21 WO disclosed
WO-1998005689-A1 POLYMERS FOR DELIVERING NITRIC OXIDE IN VIVO DUKE UNIVERSITY MEDICAL CENTER (US) 1998-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240285831-A1 METHODS OF USE OF MODULATORS TO IMPROVE NERVE REGENERATION CXCR3, CXCL12, CXCR4 ABCC1 4160/4885ALDH1A1 2426/4885MAPT 4089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.